T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia

被引:47
作者
Xia, Simo [1 ]
Liu, Xiang [1 ]
Cao, Xuetao [1 ,2 ,3 ,4 ,5 ]
Xu, Sheng [1 ]
机构
[1] Second Mil Med Univ, Inst Immunol, Natl Key Lab Med Immunol, Shanghai 200433, Peoples R China
[2] Zhejiang Univ, Inst Immunol, Sch Med, Hangzhou 310058, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll, Dept Immunol, Beijing 100005, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll, Ctr Immunotherapy, Inst Basic Med Sci, Beijing 100005, Peoples R China
[5] Nankai Univ, Coll Life Sci, Tianjin 30071, Peoples R China
基金
中国国家自然科学基金;
关键词
BTK; aplastic anemia; TCR signaling; bone marrow failure; PLC gamma 1; MOUSE MODEL; IMMUNE-RESPONSES; BTK; TEC; IBRUTINIB; LYMPHOCYTES; ITK; PATHOPHYSIOLOGY; REGULATOR; INNATE;
D O I
10.1038/s41423-019-0270-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The role of Bruton's tyrosine kinase (BTK) in BCR signaling is well defined, and BTK is involved in B-cell development, differentiation, and malignancies. However, the expression of Btk in T cells and its role in T-cell function remain largely unknown. Here, we unexpectedly found high expression and activation of BTK in T cells. Deficiencies in BTK resulted in the impaired activation and proliferation of autoreactive T cells and ameliorated bone marrow failure (BMF) in aplastic anemia. Mechanistically, BTK is activated after TCR engagement and then phosphorylates PLC gamma 1, thus promoting T-cell activation. Treatment with acalabrutinib, a selective BTK inhibitor, decreased T-cell proliferation and ameliorated BMF in mice with aplastic anemia. Our results demonstrate an unexpected role of BTK in optimal T-cell activation and in the pathogenesis of autoimmune aplastic anemia, providing insights into the molecular regulation of T-cell activation and the pathogenesis of T-cell-mediated autoimmune disease.
引用
收藏
页码:1042 / 1052
页数:11
相关论文
共 50 条
  • [1] Multidomain Control Over TEC Kinase Activation State Tunes the T Cell Response
    Andreotti, Amy H.
    Joseph, Raji E.
    Conley, James M.
    Iwasa, Janet
    Berg, Leslie J.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 36, 2018, 36 : 549 - 578
  • [2] BRUTON TYROSINE KINASE IS TYROSINE-PHOSPHORYLATED AND ACTIVATED IN PRE-B LYMPHOCYTES AND RECEPTOR-LIGATED B-CELLS
    AOKI, Y
    ISSELBACHER, KJ
    PILLAI, S
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (22) : 10606 - 10609
  • [3] Tyrosine Kinase Btk Is Required for NK Cell Activation
    Bao, Yan
    Zheng, Jian
    Han, Chaofeng
    Jin, Jing
    Han, Huanxing
    Liu, Yinping
    Lau, Yu-Lung
    Tu, Wenwei
    Cao, Xuetao
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (28) : 23769 - 23778
  • [4] Tec family kinases in T lymphocyte development and function
    Berg, LJ
    Finkelstein, LD
    Lucas, JA
    Schwartzberg, PL
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 : 549 - 600
  • [5] A mouse model of lymphocyte infusion-induced bone marrow failure
    Bloom, ML
    Wolk, AG
    Simon-Stoos, KL
    Bard, JS
    Chen, J
    Young, NS
    [J]. EXPERIMENTAL HEMATOLOGY, 2004, 32 (12) : 1163 - 1172
  • [6] MUTATION DETECTION IN THE X-LINKED AGAMMAGLOBULINEMIA GENE, BTK, USING SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS
    BRADLEY, LAD
    SWEATMAN, AK
    LOVERING, RC
    JONES, AM
    MORGAN, G
    LEVINSKY, RJ
    KINNON, C
    [J]. HUMAN MOLECULAR GENETICS, 1994, 3 (01) : 79 - 83
  • [7] FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
    de Claro, R. Angelo
    McGinn, Karen M.
    Verdun, Nicole
    Lee, Shwu-Luan
    Chiu, Haw-Jyh
    Saber, Haleh
    Brower, Margaret E.
    Chang, C. J. George
    Pfuma, Elimika
    Habtemariam, Bahru
    Bullock, Julie
    Wang, Yun
    Nie, Lei
    Chen, Xiao-Hong
    Lu, Donghao
    Al-Hakim, Ali
    Kane, Robert C.
    Kaminskas, Edvardas
    Justice, Robert
    Farrell, Ann T.
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3586 - 3590
  • [8] DeZern AE, 2011, EXPERT REV HEMATOL, V4, P221, DOI [10.1586/ehm.11.11, 10.1586/EHM.11.11]
  • [9] Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
    Dubovsky, Jason A.
    Flynn, Ryan
    Du, Jing
    Harrington, Bonnie K.
    Zhong, Yiming
    Kaffenberger, Benjamin
    Yang, Carrie
    Towns, William H.
    Lehman, Amy
    Johnson, Amy J.
    Muthusamy, Natarajan
    Devine, Steven M.
    Jaglowski, Samantha
    Serody, Jonathan S.
    Murphy, William J.
    Munn, David H.
    Luznik, Leo
    Hill, Geoffrey R.
    Wong, Henry K.
    MacDonald, Kelli K. P.
    Maillard, Ivan
    Koreth, John
    Elias, Laurence
    Cutler, Corey
    Soiffer, Robert J.
    Antin, Joseph H.
    Ritz, Jerome
    Panoskaltsis-Mortari, Angela
    Byrd, John C.
    Blazar, Bruce R.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (11) : 4867 - 4876
  • [10] Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
    Dubovsky, Jason A.
    Beckwith, Kyle A.
    Natarajan, Gayathri
    Woyach, Jennifer A.
    Jaglowski, Samantha
    Zhong, Yiming
    Hessler, Joshua D.
    Liu, Ta-Ming
    Chang, Betty Y.
    Larkin, Karilyn M.
    Stefanovski, Matthew R.
    Chappell, Danielle L.
    Frissora, Frank W.
    Smith, Lisa L.
    Smucker, Kelly A.
    Flynn, Joseph M.
    Jones, Jeffrey A.
    Andritsos, Leslie A.
    Maddocks, Kami
    Lehman, Amy M.
    Furman, Richard
    Sharman, Jeff
    Mishra, Anjali
    Caligiuri, Michael A.
    Satoskar, Abhay R.
    Buggy, Joseph J.
    Muthusamy, Natarajan
    Johnson, Amy J.
    Byrd, John C.
    [J]. BLOOD, 2013, 122 (15) : 2539 - 2549